Rare diseases
Investigational molecules
Locations
Via Paolo Richiedei 16, 25064 Gussago, Italy
Centro Clinico Nemo in Gussago, Italy specialises in clinical trials of conditions such as Amyotrophic lateral sclerosis, Chronic inflammatory demyelinating polyradiculoneuropathy, MELAS syndrome, Mitochondrial encephalomyopathy, and other specialisations. This site conducts important research.
At Centro Clinico Nemo researchers are exploring innovative therapies for rare immune‑mediated neuropathies. Current studies aim to improve muscle strength and reduce relapse rates in conditions such as Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy.
These trials evaluate the effectiveness of new biologics and compare them with standard IVIg, seeking to enhance patient outcomes and quality of life.
The site’s musculoskeletal program focuses on rare muscle disorders, testing agents that can boost functional ability and delay disease progression. Studies target Myotonic Dystrophy Type 1 and Spinal Muscular Atrophy to assess improvements in motor performance and fatigue.
By measuring changes in muscle strength and daily activity scores, investigators aim to identify treatments that restore independence for affected individuals.
Neurology research at Centro Clinico Nemo concentrates on neurodegenerative conditions, evaluating novel compounds that may slow neuronal loss. Ongoing work includes trials in Amyotrophic Lateral Sclerosis and Primary Mitochondrial Disease to determine impact on survival and functional decline.
These investigations prioritize safety and efficacy, hoping to extend life expectancy and preserve motor abilities for patients with progressive neurological disorders.
Clinical trials currently enrolling participants at this site.
A study to evaluate the effectiveness and safety of usnoflast in adults with Amyotrophic Lateral Sclerosis (ALS)
ItalyA study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1
ItalyA study to test if empasiprubart can improve function and is safe for adults with chronic inflammatory demyelinating polyneuropathy
ItalyA study testing sonlicromanol in adults with genetically confirmed mitochondrial DNA 3243A>G variant causing mitochondrial disease
ItalyA Study of IMVT-1402 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy to Prevent Disease Relapse
ItalyStudy of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo
ItalyStudy on the Effects of Acetylcarnitine Hydrochloride in Patients with Amyotrophic Lateral Sclerosis (ALS)
ItalyStudy comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy
ItalyStudy of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression
ItalyStudy of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History
ItalyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
